Skyline, Clavis Partner on Biomarkers for AML Drug | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Skyline Diagnostics and Clavis Pharma today announced a deal to investigate gene expression biomarkers that may help determine which patients will benefit from a drug compound being developed for treating acute myeloid leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.